Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network

Immunologic Research

Volumn 64, Issue 3, 2016, Pages 736-753

  Modell, Vicki ^a   Quinn, Jessica ^a   Orange, Jordan ^b   Notarangelo, Luigi D ^c   Modell, Fred ^a  

^a Jeffrey Modell Foundation   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Awareness; Diagnosis; Education; Gene discovery; Immunology; Jeffrey Modell Centers Network (JMCN); Jeffrey Modell Foundation (JMF); Primary immunodeficiencies (PI); Treatment

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN; VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; ATAXIA TELANGIECTASIA; AWARENESS; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; ECONOMIC ASPECT; FEMALE; GENE THERAPY; GEOGRAPHIC DISTRIBUTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; INCREMENTAL COST EFFECTIVE RATIO; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; NEWBORN SCREENING; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN EDUCATION; PHYSICIAN OFFICE WAITING ROOM; POLIOMYELITIS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK ASSESSMENT; SCHOOL CHILD; SEVERE COMBINED IMMUNODEFICIENCY; SEX DIFFERENCE; T CELL LYMPHOPENIA; WARD; YOUNG ADULT; COST; ECONOMICS; IMMUNOLOGY; NEWBORN; NON PROFIT ORGANIZATION; PATIENT EDUCATION; PRIVATE SECTOR; UNITED STATES;

COSTS AND COST ANALYSIS; EARLY DIAGNOSIS; EDUCATION, MEDICAL; FEMALE; FOUNDATIONS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PATIENT EDUCATION AS TOPIC; PATIENT OUTCOME ASSESSMENT; PRIVATE SECTOR; UNITED STATES; VIRAL VACCINES;

EID: 84955251310     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-016-8784-z     Document Type: Article

References (50)

1. Modell V. The impact of physician education and public awareness on early diagnosis of primary immunodeficiencies. Immunol Res. 2007;38:43–7.
2. Modell F. Immunology today and new discoveries: building upon legacies of Dr. Robert A. Good. Immunol Res. 2007;38:48–50.
3. Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5:880–92.
4. Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.
5. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyam S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang MLK. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015. doi:10.1007/s10875-015-0198-5.
6. Bousifiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, Abel L. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.
7. U.S. Department of Health and Human Services. National Institutes of Health. PAR-12-036: investigations on primary immunodeficiency diseases (R01). http://grants.nih.gov/grants/guide/pa-files/PAR-15-130.html. Retrieved 29 Oct 2015.
8. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.
9. Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res. 2009;44(1–3):132–49.
10. Buckley RH, Schiff SE, Schif RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508–16.
11. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol. 2012;129(3):607–16.
12. Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.
13. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49:25–43.
14. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–8.
15. Patel NC, et al. Outcomes of severe combined immunodeficiency patients treated with hematopoietic stem cell transplantation with and without pre-conditioning. J Allergy Clin Immunol. 2009;124(5):1062–9.e1–4.
16. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of hemopoietic stem cells for immunodeficiencies; report of the European experience 1986–1999. Lancet. 2003;361(9357):553–60.
17. Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–24.
18. Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the Global Polio Eradication Initiative. PLoS Pathog. 2015;11(8):e1005114. doi:10.1371/journal.ppat.1005114.
19. Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM, Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):640–6.
20. Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33:1235–42.
21. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Puck J, Sullivan KE, Tang MLK, Franco JL, Gaspar HB. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol. 2015. doi:10.1007/s10875-015-0201-1.
22. NIHCM Foundation. Employer-sponsored Health Insurance: Recent Trends and Future Directions. NIHCM Data Brief. 2013.
23. Lipstein EA, et al. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. Pediatrics. 2010;125:e1226–35. doi:10.1542/peds.2009-1567.
24. Centers for Disease Control and Prevention. Poliovirus laboratory testing. http://www.cdc.gov/polio/us/lab-testing/index.html.
25. Agency for Healthcare Research and Quality. http://www.hcup.ahrq.gov (2015).
26. Aetna Member Navigator. http://www.aetna.com (2015).
27. Bundorf KM, Royalty A, Baker LC. Health care cost growth among the privately insured. Health Aff. 2009;28(5):1294–304.
28. Truven Health Analytics. Healthcare Spending Index for Employer-Sponsored Insurance. 2014.
29. Centers for Medicare and Medicaid Services. Berenson-eggers type of service (BETOS). 2015. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/BETOS.html.
30. Centers for Medicare and Medicaid Services. Medicare current beneficiary survey (MCBS). 2015. https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/MCBS/index.html?redirect=/mcbs.
31. Congressional Budget Office. Factors underlying the growth in medicare’s spending for physicians’ services. 2007. Retrieved 28 Apr 2010, from http://www.cbo.gov/ftpdocs/81xx/doc8193/06-06-MedicareSpending.pdf.
32. Fronstin P. Sources of health insurance and characteristics of the uninsured: analysis of the March 2013 current population survey, vol 390. EBRI (Employee Benefit Research Institute) Issue Brief No. 390, September 2013, Washington, DC; 2013. p. 1–36.
33. Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.
34. Health Care Cost Institute (HCCI). 2014 Health Care Cost and Utilization Report. 2015. http://www.healthcostinstitute.org/files/2014%20HCCUR%2010.29.15.pdf.
35. Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy. Clinicoecon Outcomes Res. 2014;6:297–302.
36. Denno MS, Popelar B, Abdel-Sattar M, et al. Managed care perceptions and utilization of outcomes analyzers in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting; Tampa, FL: 2014.
37. Sebelius K. Letter to the committee chairperson for the Secretary’s advisory committee on heritable disorders in newborns and children US Department of Health and Human Services. 2010. http://tinyurl.com/l9baeng.
38. National Vital Statistics Reports, vol. 64, No. 1. 2015. http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_01.pdf.
39. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38. doi:10.1001/jama.2014.9132.
40. Caggana M, Brower A, Baker M, Comeau AM, Lorey F. National SCID Pilot Study. http://preview.tinyurl.com/lsanbqh.
41. Kuehn BM. State, federal efforts under way to identify children with ‘‘Bubble Boy Syndrome’’. JAMA. 2010;304(16):1771–3.
42. Appelbaum B. As US agencies put more value on a life, businesses fret [Newspaper]. New York Times. 2011. http://tinyurl.com/mlynth7. Accessed 16 Aug 2013.
43. Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, Lewis DB, McGhee SA, Moore TB, Stiehm ER, Porteus M, Aznar CP, Currier R, Lorey F, Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132(1):140–50.
44. CBCNews Canada. ‘Bubble boy’ welcomes new Ontario screening test. Published online Aug 20, 2013. http://www.cbc.ca/news/canada/story/2013/08/20/newborn-screening-bubble-boyscid.html. Accessed 21 Aug 2013.
45. Hospital Cost and Utilization Project (HCUP), Nationwide Inpatient Database under the auspices of the Agency for Healthcare Research and Quality (AHRQ). ICD-9 CM Principal Diagnosis Code for HSCT.
46. Centers for Medicare and Medicaid Services, Hospital Accounting Records. 2010.
47. Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Immunology. 2013;13:635–48.
48. Bharat ST, Alizadehfar R, Desrosiers M, Shuster J, Pant N, Tsoukasa CM. Adult primary immune deficiency: what are we missing? Am J Med. 2012;125(8):779–86.
49. Pollack A. Jennifer Doudna, a Pioneer Who Helped Simplify Genome Editing. Profiles in Science, NY Times. 2015. http://www.nytimes.com/2015/05/12/science/jennifer-doudna-crispr-cas9-genetic-engineering.html?_r=0. Accessed 13 May 2015.
50. Keller MD, Bollard CM, Hanley PJ, McCormack S, Heimall J, Bunin N, Loechelt B, Jyonouchi S. Viral-specific T lymphocytes for treatment of viral infections in primary immunodeficiency. Biol Blood Marrow Trans. 2015;21(2):S229–30.